Accessory molecules for MHC class II peptide loading

Current Opinion in Immunology

Volumn 12, Issue 1, 2000, Pages 99-106

  Busch, Robert ^a   Doebele, Robert C ^a,b   Patil, Namrata S ^a   Pashine, Achal ^a   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DM ANTIGEN; HLA DO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TETRASPANIN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; GENE TARGETING; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 0033961517     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00057-6     Document Type: Review

References (80)

1. Busch R., Mellins E.D. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol. 8:1996;51-58.
2. Ashman J.B., Miller J. A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain. J Immunol. 163:1999;2704-2712. This paper shows that residues of the transmembrane region, located near the luminal side, are critical for Ii to trimerize and assemble with MHC class II.
3. Anderson H.A., Roche P.A. Phosphorylation regulates the delivery of MHC class II invariant chain complexes to antigen processing compartments. J Immunol. 160:1998;4850-4858. This paper shows that the amino-terminal extension of the p35/p43 Ii cytoplasmic tail is phosphorylated at key serine residues in human APC lines and provides evidence that this phosphorylation is critical for direct delivery of these Ii isoforms from the trans-Golgi reticulum to MIIC.
4. b.
5. Pond L., Watts C. Characterization of transport of newly assembled, T cell-stimulatory MHC class II-peptide complexes from MHC class II compartments to the cell surface. J Immunol. 159:1997;543-553.
6. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., Geuze H.J. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 183:1996;1161-1172.
7. Manoury B., Hewitt E.W., Morrice N., Dando P.M., Barrett A.J., Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature. 396:1998;695-699. This paper shows that proteolytic processing of native proteins in lysosomal extracts can be initiated by an asparaginyl endopeptidase.
8. Jensen P.E. Acidification and disulfide reduction can be sufficient to allow intact proteins to bind class II MHC. J Immunol. 150:1993;3347-3356.
9. Jensen P.E. Antigen unfolding and disulfide reduction in antigen presenting cells. Semin Immunol. 7:1995;347-353.
10. Carrasco-Marin E., Paz-Miguel J.E., Lopez-Mato P., Alvarez-Dominguez C., Leyva-Cobian F. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Immunology. 95:1998;314-321.
11. Aichinger G., Karlsson L., Jackson M.R., Vestberg M., Vaughan J.H., Teyton L., Lechler R.I., Peterson P.A. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J Biol Chem. 272:1997;29127-29136.
12. Pinet V., Vergelli M., Martin R., Bakke O., Long E.O. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature. 375:1995;603-606.
13. Pinet V.M., Long E.O. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur J Immunol. 28:1998;799-804.
14. Vergelli M., Pinet V., Vogt A.B., Kalbus M., Malnati M., Riccio P., Long E.O., Martin R. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. Eur J Immunol. 27:1997;941-951.
15. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature. 388:1997;782-787.
16. Pierre P., Turley S.J., Gatti E., Hull M., Meltzer J., Mirza A., Inaba K., Steinman R.M., Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature. 388:1997;787-792.
17. Pierre P., Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 93:1998;1135-1145. This paper shows that in immature murine dendritic cells, grown in granulocyte/macrophage-colony-stimulating factor plus IL-3, lysosomal Ii proteolysis by cathepsin S is blocked by cystatin C. Relief of this inhibition upon maturation allows Ii proteolysis, peptide loading, and export of MHC class II to the cell surface to proceed.
18. Swier K., Brown D.R., Bird J.J., Martin W.D., Van Kaer L., Reiner S.L. A critical, invariant chain-independent role for H2-M in antigen presentation. J Immunol. 160:1998;540-544. This paper shows, using double-knockout mice, that Ii is dispensable for protection of mice against progressive infection with Leishmania major, and that both in the presence and absence of Ii, protection requires H2-M.
19. b-bound endogenous peptides in knockout mice lacking H2-M, Ii, or both. These peptides are presented at almost wild-type levels in the absence of Ii; none are presented in H2-M single knockouts, and varying levels of presentation are seen when both Ii and H2-M are absent.
20. Bikoff E.K., Kenty G., Van Kaer L. Distinct peptide loading pathways for MHC class II molecules associated with alternative Ii chain isoforms. J Immunol. 160:1998;3101-3110.
21. Tourne S., Nakano N., Viville S., Benoist C., Mathis D. The influence of invariant chain on the positive selection of single T cell receptor specificities. Eur J Immunol. 25:1995;1851-1856.
22. Surh C.D., Lee D.S., Fung-Leung W.P., Karlsson L., Sprent J. Thymic selection by a single MHC/peptide ligand produces a semidiverse repertoire of CD4+ T cells. Immunity. 7:1997;209-219.
23. 0/0 mice. Immunity. 7:1997;187-195.
24. Bikoff E.K., Germain R.N., Robertson E.J. Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity. 2:1995;301-310.
25. Rovere P., Forquet F., Zimmermann V.S., Trucy J., Ricciardi-Castagnoli P., Davoust J. Dendritic cells from mice lacking the invariant chain express high levels of membrane MHC class II molecules in vivo. Adv Exp Med Biol. 417:1997;195-201.
26. + T cells in the periphery and secondary proliferative responses elicited upon peptide challenge. J Immunol. 163:1999;232-241.
27. Tourne S., Miyazaki T., Wolf P., Ploegh H., Benoist C., Mathis D. Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H-2M complexes. Proc Natl Acad Sci USA. 94:1997;9255-9260.
28. 0 mice than in single knockouts.
29. Katz J.F., Stebbins C., Appella E., Sant A.J. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med. 184:1996;1747-1753.
30. Lightstone L., Hargreaves R., Gabriele B., Peterson M., Aichinger G., Lombardi G., Lechler R. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc Natl Acad Sci USA. 94:1997;5772-5777.
31. Ghosh P., Amaya M., Mellins E., Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature. 378:1995;457-462.
32. g7.
33. Siebenkotten I.M., Carstens C., Koch N. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes. J Immunol. 160:1998;3355-3362. Using Ii molecules in which groove-binding and adjacent regions of CLIP were replaced by antigenic peptide or nonsense sequences, this paper and [34] show that Ii residues 81-87 contribute to allele-independent MHC class II binding.
34. Stumptner P., Benaroch P. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. EMBO J. 16:1997;5807-5818.
35. Barton G.M., Rudensky A.Y. An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class II αβ dimers and facilitates highly efficient peptide loading. Int Immunol. 10:1998;1159-1165.
36. Thayer W.P., Ignatowicz L., Weber D.A., Jensen P.E. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules. J Immunol. 162:1999;1502-1509. Using amino- and carboxy-terminal truncations of Ii, this paper shows that a region immediately carboxy-terminal to CLIP (residues 103-118) and the trimerization domain cooperate to mediate binding to MHC class II outside the antigen binding groove.
37. Jasanoff A., Song S., Dinner A.R., Wagner G., Wiley D.C. One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules. Immunity. 761:1999;761-768. This paper shows that except for the trimerization domain, E. coli-derived soluble Ii (72-216) is disordered in solution, as demonstrated by sharp peaks in nuclear magnetic resonance spectra. Residues on either side of the CLIP region become ordered upon binding to DR, resulting in broadening of spectral peaks.
38. Jasanoff A., Wagner G., Wiley D.C. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J. 17:1998;6812-6818. This paper uses an ingenious combination of differential isotope labeling of Ii chains and multidimensional nuclear magnetic resonance to determine the structure of the luminal Ii trimerization domain in solution. This domain adopts a novel fold employing numerous interchain contacts to form a roughly cylindrical structure allowing assembly of three MHC class II αβ dimers around its lateral faces.
39. Guncar G., Pungercic G., Klemencic I., Turk V., Turk D. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18:1999;793-803. This study shows by X-ray crystallography that the alternatively spliced cathepsin L inhibitor domain in Ii p41 adopts a novel variant of the thyroglobulin domain fold. Inhibitory interactions with cathepsin L are reminiscent of those found for cystatins, but additional contacts not seen for cystatins account for target enzyme specificity.
40. Sanderson S., Frauwirth K., Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci USA. 92:1995;7217-7221.
41. Malcherek G., Wirblich C., Willcox N., Rammensee H-G., Trowsdale J., Melms A. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur J Immunol. 28:1998;1524-1533.
42. Fujii S., Senju S., Chen Y.Z., Ando M., Matsushita S., Nishimura Y. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol. 59:1998;607-614.
43. •].
44. •] demonstrate the use of cDNA libraries expressed as fusion constructs with the Ii amino terminus for expression cloning of MHC-class-II-restricted tumor antigens.
45. Siklodi B., Vogt A.B., Kropshofer H., Falcioni F., Molina M., Bolin D.R., Campbell R., Hämmerling G.J., Nagy Z.A. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells. Hum Immunol. 59:1998;463-471.
46. Weber D.A., Evavold B.D., Jensen P.E. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 274:1996;618-620.
47. Van Ham S.M., Grüneberg U., Malcherek G., Bröker I., Melms A., Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med. 184:1996;2019-2024.
48. Raddrizzani L., Bono E., Vogt A.B., Kropshofer H., Gallazzi F., Sturniolo T., Hämmerling G.J., Sinigaglia F., Hammer J. Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Eur J Immunol. 29:1999;660-668. This paper describes direct binding assays using synthetic peptides and random peptide phage display libraries to identify glycine and proline residues at anchor and non-anchor positions within peptides as residues that decrease MHC class II complex stability and increase susceptibility to release by DM.
49. Vogt A.B., Kropshofer H., Moldenhauer G., Hämmerling G.J. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA. 93:1996;9724-9729.
50. Sanderson F., Thomas C., Neefjes J., Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity. 4:1996;87-96.
51. Denzin L.K., Hammond C., Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med. 184:1996;2153-2165.
52. Kropshofer H., Arndt S.O., Moldenhauer G., Hämmerling G.J., Vogt A.B. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity. 6:1997;293-302.
53. Schafer P.H., Green J.M., Malapati S., Gu L., Pierce S.K. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J Immunol. 157:1996;5487-5495.
54. •].
55. ••] show that binding of labeled peptides to MHC class II is greatly accelerated when the MHC class II molecules are first preloaded with unlabeled peptides that dissociate rapidly. Further analysis reveals evidence for an active MHC class II conformation capable of rapid peptide binding, which is generated upon peptide release but inactivates rapidly.
56. Zarutskie J.A., Sato A.K., Rushe M.M., Chan I.C., Lomakin A., Benedek G.B., Stern L.J. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Biochemistry. 38:1999;5878-5887. This paper shows that empty, soluble DR1 molecules expressed in E. coli have a more open conformation than peptide-loaded DR1, using ultracentrifugation, gel filtration, circular dichroism spectroscopy and antibody binding to analyse conformational changes.
57. d molecules at the cell surface (in the absence of Ii) or in their rapid endosomal turnover (when Ii is present).
58. Denzin L.K., Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell. 82:1995;155-165.
59. Mellins E., Cameron P., Amaya M., Goodman S., Pious D., Smith L., Arp B. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med. 179:1994;541-549.
60. Sloan V.S., Cameron P., Porter G., Gammon M., Amaya M., Mellins E., Zaller D.M. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 375:1995;802-806.
61. Guerra C.B., Busch R., Doebele R.C., Liu W., Sawada T., Kwok W.W., Chang M., Mellins E.D. Novel glycosylation of HLA-DRα disrupts antigen presentation without altering endosomal localization. J Immunol. 160:1998;4289-4297.
62. ••].
63. ••] show, using X-ray crystallography, that HLA-DM and H2-M fold like MHC class II molecules, except that they lack a peptide-binding groove due to apposition of the α-helical regions of the α1 and β1 domains at several points. Different MHC class II contact surfaces of DM are proposed.
64. Kelly A.P., Monaco J.J., Cho S.G., Trowsdale J. A new human HLA class II-related locus, DM. Nature. 353:1991;571-573.
65. Busch R., Doebele R.C., von Scheven E., Fahrni J., Mellins E.D. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. J Immunol. 160:1998;734-743.
66. Busch R., Reich Z., Zaller D.M., Sloan V., Mellins E.D. Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. J Biol Chem. 273:1998;27557-27564. This paper shows that transmembrane regions and/or cytoplasmic tails of both DM and DR are important for their optimal interaction. Circular dichroism and fluorescence spectroscopy reveal substantial pH-dependent conformational changes in soluble DM.
67. Reich Z., Altman J.D., Boniface J.J., Lyons D.S., Kozono H., Ogg G., Morgan C., Davis M.M. Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. Proc Natl Acad Sci USA. 94:1997;2495-2500.
68. Ullrich H.J., Döring K., Grüneberg U., Trowsdale J., Van Ham S.M. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc Natl Acad Sci USA. 94:1997;13163-13168.
69. Karlsson L., Surh C.D., Sprent J., Peterson P.A. A novel class II MHC molecule with unusual tissue distribution. Nature. 351:1991;485-488.
70. b molecules is normal, but presentation of antigens taken up via specific surface immunoglobulin is reduced. In vitro, soluble DM-DO constructs are active over a narrower pH range, representative of late endosomes, than DM alone.
71. Douek D.C., Altmann D.M. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol. 9:1997;355-364.
72. Liljedahl M., Kuwana T., Fung-Leung W.P., Jackson M., Peterson P.A., Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 15:1996;4817-4824.
73. Denzin L.K., Sant'Angelo D.B., Hammond C., Surman M.J., Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science. 278:1997;106-109.
74. Van Ham S.M., Tjin E.P.M., Lillemeier B.F., Grüneberg U., Van Meijgaarden K.E., Pastoors L., Verwoerd D., Tulp A., Canas B., Rahman D.et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol. 7:1997;950-957.
75. Kropshofer H., Vogt A.B., Thery C., Armandola E.A., Li B.C., Moldenhauer G., Amigorena S., Hämmerling G.J. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 17:1998;2971-2981. This study shows that DM is expressed at low levels relative to DM in EBV-B cells and that at these ratios, DO improves DM-dependent CLIP release and alters the peptide profile of DR4 molecules in transfected melanoma cells. DM-DO complexes from human spleen or formed in vitro from recombinant molecules are more potent at enhancing peptide association and preserving peptide binding sites than DM alone, especially when using DR alleles, such as DR0401, which are unstable in the absence of DM.
76. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 11:1997;428-442.
77. Schick M.R., Levy S. The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules. J Immunol. 151:1993;4090-4097.
78. Escola J-M., Kleijmeer M.J., Stoorvogel W., Griffith J.M., Yoshie O., Geuze H.J. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 273:1998;20121-20127.
79. Hammond C., Denzin L.K., Pan M., Griffith J.M., Geuze H.J., Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol. 161:1998;3282-3291. The authors demonstrate that two tetraspanins, CD82 and CD63, localize to endosomal compartments (MIICs), where they form multimolecular complexes containing HLA-DR, HLA-DM, and HLA-DO. Although no specific function has yet been identified, these results implicate tetraspanins in antigen presentation.
80. Drbal K., Angelisova P., Rasmussen A.M., Hilgert I., Funderud S., Horejsi V. The nature of the subset of MHC class II molecules carrying the CDw78 epitopes. Int Immunol. 11:1999;491-498.